PDCD1 and cancer: Programmed cell death ligand 1 (PD-L1)/program cell death protein 1 (PD-1) and cytotoxic lymphocyte-associated antigen 4 (CTLA-4) inhibitors are two of the most common immunotherapy classes used in cancer therapeutics [1].